New Zealand markets open in 8 hours 25 minutes

Cybin Inc. (CYBN)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.2939-0.0015 (-0.51%)
As of 09:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.2954
Open0.2749
Bid0.2742 x 900
Ask0.2881 x 900
Day's range0.2900 - 0.2949
52-week range0.2480 - 0.7380
Volume140,805
Avg. volume4,316,672
Market cap223.274M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-0.1800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    What Makes Cybin Inc. (CYBN) a New Buy Stock

    Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Business Wire

    Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

    TORONTO, June 26, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health disorders, today reported audited financial results for its fiscal year ended March 31, 2024, and recent business highlights.

  • Business Wire

    Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

    TORONTO, June 19, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking place June 27, 2024.